# A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults

> **NCT04871113** · PHASE2 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 62 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** GSK3810109A
- **BIOLOGICAL:** Dolutegravir+lamivudine SOC regimen

## Key facts

- **NCT ID:** NCT04871113
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-22
- **Primary completion:** 2022-10-27
- **Final completion:** 2023-09-21
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04871113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04871113, "A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04871113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*